Drug intelligence / Profile preview

AV2-DM

Development stage: Phase 3
Lead developer: Cesa Projects International
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

AV2-DM is a topical antiviral spray investigated for reducing cervical human papillomavirus (HPV) infection viral load after a single application to the cervix. It has been developed by Cesa Projects International and evaluated in a randomized, double-blind, placebo-controlled clinical study (AV2-HPV-001; NCT01654822). Detailed mechanism of action and composition have not been publicly disclosed in accessible summaries; study materials refer to “AV2” vs placebo, with AV2-DM described as the investigational antiviral spray aiming for short‑term (3‑month) reduction in HPV viral load.[2][4][5][10]

Other names: AV2AV-2AV 2

Beyond the preview

Go deeper on AV2-DM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV2-DM.

Explore the full profile